Stock Events

Stock Events

Rezolute 

$3.95
45
-$0.17-4.13%Friday 20:00
+$0.05+1.27%Friday 23:43After hours

Statistics

Day High
3.96
Day Low
3.95
52W High
10.94
52W Low
1.4
Volume
20,814
Avg. Volume
-
Mkt Cap
382.05M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 5Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-0.27
-0.23
-0.2
-0.16
Expected EPS
-0.18537
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-77.59MNet Income

Analyst Ratings

$10.71Average Price Target
The highest estimate is ⁦15.00⁩.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
88%
Hold
13%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RZLT. It's not an investment recommendation.
NVIDIA
17
NVDA
SoFi Technologies
14
SOFI
Microsoft
13
MSFT
Alphabet
13
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap22.1B
Alnylam Pharmaceuticals, Inc. operates in the biopharmaceutical field focusing on RNAi therapeutics for the treatment of rare genetic diseases, competing in the same rare disease space as Rezolute.
Ionis Pharmaceuticals
IONS
Mkt Cap7.24B
Ionis Pharmaceuticals, Inc. develops RNA-targeted therapeutics, directly competing with Rezolute's approach to treating rare diseases through innovative therapies.
Viking Therapeutics
VKTX
Mkt Cap3.48B
Viking Therapeutics, Inc. is involved in the development of therapies for metabolic and endocrine disorders, directly competing with Rezolute's metabolic disease focus.
Seres Therapeutics
MCRB
Mkt Cap29.53M
Seres Therapeutics, Inc. is engaged in microbiome therapeutics for metabolic diseases, which places it in direct competition with Rezolute's metabolic disease treatments.
PTC Therapeutics
PTCT
Mkt Cap5.3B
PTC Therapeutics, Inc. focuses on the discovery and commercialization of novel medicines to treat rare disorders, directly competing with Rezolute in the rare disease market.
Sarepta Therapeutics
SRPT
Mkt Cap1.97B
Sarepta Therapeutics, Inc. specializes in the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases, competing in the rare disease space alongside Rezolute.

About

Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.
Show More
CEO
Nevan Charles Elam
Employees
58
Country
United States
ISIN
US76200L3096
WKN
000A2QEWP

Listings

F
DE
6HV1.F
BOATS
BOATS
RZLT.BOATS
STU
DE
6HV1.STU
MU
DE
6HV1.MU

0 Comments

Share your thoughts

FAQs

What is Rezolute stock price today?▼
The current price of RZLT is $3.95 USD — it has decreased by -4.13% in the past 24 hours. Watch Rezolute stock price performance more closely on the chart.
What is Rezolute stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Rezolute stocks are traded under the ticker RZLT.
Is Rezolute stock price growing?▼
RZLT stock has risen by +3.4% compared to the previous week, the month change is a -1.5% fall, over the last year Rezolute has showed a -57.62% decrease.
What is Rezolute market cap?▼
Today Rezolute has the market capitalization of 382.05M
When is the next Rezolute earnings date?▼
Rezolute is going to release the next earnings report on November 5, 2026.
What were Rezolute earnings last quarter?▼
RZLT earnings for the last quarter are -0.16 USD per share, whereas the estimation was -0.18 USD resulting in a +11.5% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Rezolute revenue for the last year?▼
Rezolute revenue for the last year amounts to 0 USD.
What is Rezolute net income for the last year?▼
RZLT net income for the last year is -77.59M USD.
How many employees does Rezolute have?▼
As of November 2, 2026, the company has 58 employees.
In which sector is Rezolute located?▼
Rezolute operates in the Health & Wellness sector.
When did Rezolute complete a stock split?▼
The last stock split for Rezolute was on October 13, 2020 with a ratio of 1:50.
Where is Rezolute headquartered?▼
Rezolute is headquartered in REDWOOD CITY, United States.